James  Kihara net worth and biography

James Kihara Biography and Net Worth

James Kihara serves as Principal Accounting Officer of the Company. He has been with the Company since March 2020. Prior to joining the Company, Mr. Kihara worked at Cubic Corporation, an information technology and services firm, from November 2012 to March 2020, most recently serving as chief financial officer of the Cubic Mission Solutions business segment. Prior to Cubic Corporation, Mr. Kihara was employed by Ernst & Young LLP, a multinational professional services firm, and served as a Senior Manager of Assurance Services. Mr. Kihara earned a bachelor’s degree in Business Administration (Accounting) from San Diego State University and is a certified public accountant in the State of California.

What is James Kihara's net worth?

The estimated net worth of James Kihara is at least $273,264.50 as of November 20th, 2023. Mr. Kihara owns 13,025 shares of ACADIA Pharmaceuticals stock worth more than $273,265 as of December 9th. This net worth approximation does not reflect any other assets that Mr. Kihara may own. Learn More about James Kihara's net worth.

How old is James Kihara?

Mr. Kihara is currently 42 years old. There are 4 older executives and no younger executives at ACADIA Pharmaceuticals. The oldest executive at ACADIA Pharmaceuticals is Mr. Stephen R. Davis J.D., President, CEO & Director, who is 62 years old. Learn More on James Kihara's age.

How do I contact James Kihara?

The corporate mailing address for Mr. Kihara and other ACADIA Pharmaceuticals executives is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. ACADIA Pharmaceuticals can also be reached via phone at (858) 558-2871 and via email at [email protected]. Learn More on James Kihara's contact information.

Has James Kihara been buying or selling shares of ACADIA Pharmaceuticals?

During the past quarter, James Kihara has sold $44,940.40 in shares of ACADIA Pharmaceuticals stock. Most recently, James Kihara sold 1,985 shares of the business's stock in a transaction on Monday, November 20th. The shares were sold at an average price of $22.64, for a transaction totalling $44,940.40. Following the completion of the sale, the insider now directly owns 13,025 shares of the company's stock, valued at $294,886. Learn More on James Kihara's trading history.

Who are ACADIA Pharmaceuticals' active insiders?

ACADIA Pharmaceuticals' insider roster includes Laura Brege (Director), Stephen Davis (CEO), James Kihara (Insider), Austin Kim (EVP), Elena Ridloff (CFO), Mark Schneyer (CFO), Srdjan Stankovic (President), and Brendan Teehan (COO). Learn More on ACADIA Pharmaceuticals' active insiders.

Are insiders buying or selling shares of ACADIA Pharmaceuticals?

During the last year, ACADIA Pharmaceuticals insiders bought shares 1 times. They purchased a total of 209,053 shares worth more than $5,312,036.73. During the last year, insiders at the biopharmaceutical company sold shares 33 times. They sold a total of 299,850 shares worth more than $7,415,428.09. The most recent insider tranaction occured on November, 20th when COO Brendan Teehan sold 4,960 shares worth more than $112,294.40. Insiders at ACADIA Pharmaceuticals own 27.5% of the company. Learn More about insider trades at ACADIA Pharmaceuticals.

Information on this page was last updated on 11/20/2023.

James Kihara Insider Trading History at ACADIA Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2023Sell1,985$22.64$44,940.4013,025View SEC Filing Icon  
9/15/2023Sell2,000$25.88$51,760.0010,778View SEC Filing Icon  
6/15/2023Sell2,000$24.15$48,300.009,144View SEC Filing Icon  
5/17/2023Sell5,947$22.50$133,807.5011,144View SEC Filing Icon  
4/10/2023Sell523$18.14$9,487.225,197View SEC Filing Icon  
4/6/2023Sell701$18.16$12,730.164,231View SEC Filing Icon  
2/24/2023Sell350$18.78$6,573.002,923View SEC Filing Icon  
4/8/2022Sell1,025$27.05$27,726.252,433View SEC Filing Icon  
2/23/2022Sell359$23.80$8,544.20View SEC Filing Icon  
See Full Table

James Kihara Buying and Selling Activity at ACADIA Pharmaceuticals

This chart shows James Kihara's buying and selling at ACADIA Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ACADIA Pharmaceuticals Company Overview

ACADIA Pharmaceuticals logo
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $20.98
Low: $20.87
High: $21.73

50 Day Range

MA: $22.49
Low: $20.78
High: $24.07

2 Week Range

Now: $20.98
Low: $14.48
High: $33.99


1,440,135 shs

Average Volume

1,141,636 shs

Market Capitalization

$3.44 billion

P/E Ratio


Dividend Yield